Abpro Holdings, Inc. operates as a capital pool company. The company is headquartered in New York City, New York and currently employs 6 full-time employees. The company went IPO on 2022-01-14. The firm is advancing a pipeline of next generation antibody therapies for human epidermal growth factor receptor 2 (HER2)+cancers, non-HER2+ gastric and liver cancer, and wet age-related macular degeneration and diabetic macular edema. These antibodies are developed using the Company’s proprietary DiversImmune platform. Its two lead product candidates, ABP-102 and ABP-201, feature its next generation tetravalent antibody format (TetraBi antibody format), which binds to two different targets with two distinct binding sites per target. ABP-102 is designed to redirect a patient’s immune system to fight cancer by engaging T cells through co-targeting HER2, and CD3, T-cell co-receptor. ABP-201 is designed to block blood vessel formation and normalize damaged vessels through co-targeting VEGF and ANG-2. The company plans to develop ABP-201 to treat vascular disease of the eye, focusing on wet age-related macular degeneration (Wet AMD).
Follow-Up Questions
ABPRO Holdings Inc のCEOは誰ですか？
Mr. Jin Wook Suk は ABPRO Holdings Inc の Chairman of the Board で、2024 から在籍しています。
ABP の株価パフォーマンスは？
ABP の現在の価格は $0.2 で、最終取引日から 0% increased 変動しました。
ABPRO Holdings Inc の主な事業テーマや業界は？
ABPRO Holdings Inc は Biotechnology 業界、セクターは Health Care に属しています。
